Buradasınız

Anasayfa » Content

Research and Development, Exports and Patenting in the Indian Pharmaceutical Industry: a Post TRIPS Analysis

Journal Name:

  • Eurasian Journal of Business and Economics

Publication Year:

  • 2011

Key Words:

Author Name
Abstract (2. Language): 
The Pharmaceutical Industry witnessed a change after the formation of World Trade Organization (WTO) in 1995 when India, being a signatory member of WTO, adopted Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. Indian pharmaceutical industry, being a highly fragmented one and dominated mostly by a large number of smaller enterprises, was also apprehensive when TRIPS was included in WTO. In the above backdrop, this paper examines the Impact of TRIPS on Research and Development, Exports and Patenting activity of The Pharmaceutical Industry of India. The results of the study highlight an increase in R & D Expenses, and R& D Intensity of leading Pharmaceutical companies in the Post- TRIPs period. Moreover, the Indian companies have been at the forefront, both in terms of Drug Master Filings (DMF) and abbreviated New Drug Applications (ANDA) filings in post TRIPS period.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-research-and-development-exports-and-patenting-indian-pharmaceutical-industry-post-trips-analysis.pdf
  • 7
53-67
  • English

JEL Codes:

REFERENCES

References: 

Bell, M and K.Pavitt (1993) “Technological accumulation and industrial growth: contrasts
between developed world and developing countries”, Industrial and corporate change,
Vol.2, no.2, pp157-210Business Standard 2009 “Pharma companies on DMF filing spree”
Sept 2009.
Business Line (2006) “Indian pharma companies top DMF filings” Aug. 2006.
Chadha, A. (2005) “TRIPS and Patenting Activity: Evidence from the Indian Pharmaceutical
Industry”, National University of Singapore, Department of Economics, working paper no
0512 retrieved from http://nt2.fas.nus.sg/ecs/pub/wp/wp0512.pdf.
Chadda, A. (2006) “Destination india - the right choice for the pharmaceutical industry”,
Delhi Business Review Vol. 7, No. 1 (January - June 2006) pp 1-8
Chaudhuri, S. (2007) “Is Product Patent Protection Necessary in Developing Countries for
Innovation? R&D by Indian Pharmaceutical Companies after TRIPS” Working Paper Series
WPS No. 614/ September 2007 retrieved from
http://www.iimcal.ac.in/res/upd/Sudip20Wp20614.pdf.
Chaturvedi, K. and Chataway,J., (2006) , “ Innovation In The Post-Trips Regime In Indian
Pharmaceutical Firms: Implications For Pharmaceutical Innovation Model”, International
Journal of Business Innovation and Research , Volume 1, Number 1-2 , pp 27-50.
Dhar, B. and Gopakumar, K.M. (2006) “Post-2005 TRIPS scenario in patent protection in the
pharmaceutical sector: The case of the generic pharmaceutical industry in India” the
UNCTAD/ICTSD Project on Intellectual Property Rights and Sustainable Development
November.
Export Import Bank of India (2007) “Indian Pharmaceutical Industry: Surging Globally”,
Occasional Paper No 119, Quest Publications.
Express Pharma, (2008) “The preferred API partner” 16-30 Sept.
Grace, C. (2004) “The Effect of Changing Intellectual Property on Pharmaceutical Industry
Prospects in India and China: Considerations for Access to Medicines”, DFID Health system
resource centre: London 2004
Gupta, Desh Bandhu, (2007), “Exciting Opportunities for the Indian Pharmaceutical
Industry”, Indian Chemical Engineer ,Vol. 49 No. 2 April-June 2007, pp. 154-157
Kubo, K. 2004 “Product patents and vertical integration in the Post- TRIPS Indian
Pharmaceutical Industry”, retrieved from http://are.berkeley.edu/jobmarket/ken.pdf.
Lall, S (1987), Learning to industrialize: the acquisition of technological capability by India,
London : Macmillan press.
Lanjouw, J. O. (1998) “The introduction of pharmaceutical product patents in India: Heartless
exploitation of the poor and suffering?” NBER working paper No.6366, National Bureau of
Economic Research, Cambridge.
Lanjouw, J.O., and Cockburn, I.M. (2001) “New pills for poor people? Empirical evidence
after GATT”, World Development, 29(2) February, 265-289.
Lanjouw, J.O., and MacLeod, M. (2005) “Statistical trends in pharmaceutical research for
poor countries”, CIPIH Working Paper.
Mishra P., and Chandra T. (2010) “Mergers, Acquisitions and Firm’s Performance: Experience
of Indian Pharmaceutical Industry”, Eurasian Journal of Business and Economics 3(5), 111-
126.
Pradhan, J.P. (2006) “Strengthening Intellectual Property Rights Globally: Impact on India's
Pharmaceutical Exports”, ISID Working Paper No 2006/02.
Ravi Kiran and Mishra, Sunita (2010) “New IPR Regime and Challenges of the Small Pharma
Industry”, Interdisciplinary journal of Contemporary Research in Business, Vol.1, No 10. pp
42-60.
Ravi Kiran and Sunita Mishra (2009) “Performance of the Indian Pharmaceutical Industry in
Post- TRIPS Period: A Firm Level Analysis”, International Review of Business Research Papers,
Vol.5, No. 6, pp 148-160.
Ravi Kiran and Mishra, Sunita (2009) “Changing Pragmatics of The Indian Pharmaceutical
Industry in Pre and Post-TRIPS Period” International Journal of Business & Management, Vol.
4, No 9, pp 206-220.
Reddy, S. (2006) “The Costs to India of Complying with World Intellectual Property Rights:
Effects on the Pharmaceutical Industry and Access to Drugs” Economics Thesis.
Wendt, R. A. (2000) “The Pharmaceutical Industry in India”, in Handelshoejskolen i
Koebenhavn. Institut for Informatik, International Development Studies, Roskilde University
Working Paper No. 24, pp 18 www.ruc.dk/isg_en/

Thank you for copying data from http://www.arastirmax.com